115 related articles for article (PubMed ID: 31549752)
1. Erufosine (ErPC3) Cationic Prodrugs as Dual Gene Delivery Reagents for Combined Antitumor Therapy.
Gaillard B; Seguin C; Remy JS; Pons F; Lebeau L
Chemistry; 2019 Dec; 25(68):15662-15679. PubMed ID: 31549752
[TBL] [Abstract][Full Text] [Related]
2. Synthesis and Evaluation of Antitumor Alkylphospholipid Prodrugs.
Gaillard B; Remy JS; Pons F; Lebeau L
Pharm Res; 2020 May; 37(6):106. PubMed ID: 32462253
[TBL] [Abstract][Full Text] [Related]
3. Dual Gene Delivery Reagents From Antiproliferative Alkylphospholipids for Combined Antitumor Therapy.
Gaillard B; Remy JS; Pons F; Lebeau L
Front Chem; 2020; 8():581260. PubMed ID: 33134279
[TBL] [Abstract][Full Text] [Related]
4. Differential effects of erufosine on proliferation, wound healing and apoptosis in colorectal cancer cell lines.
Kaleağasıoğlu F; Berger MR
Oncol Rep; 2014 Mar; 31(3):1407-16. PubMed ID: 24366062
[TBL] [Abstract][Full Text] [Related]
5. The translocator protein radioligand 18F-DPA-714 monitors antitumor effect of erufosine in a rat 9L intracranial glioma model.
Awde AR; Boisgard R; Thézé B; Dubois A; Zheng J; Dollé F; Jacobs AH; Tavitian B; Winkeler A
J Nucl Med; 2013 Dec; 54(12):2125-31. PubMed ID: 24212976
[TBL] [Abstract][Full Text] [Related]
6. Erufosine increases RhoB expression in oral squamous carcinoma cells independent of its tumor suppressive mode of action - a short report.
Ansari SS; Akgün N; Berger MR
Cell Oncol (Dordr); 2017 Feb; 40(1):89-96. PubMed ID: 27812856
[TBL] [Abstract][Full Text] [Related]
7. Erufosine, a novel alkylphosphocholine, in acute myeloid leukemia: single activity and combination with other antileukemic drugs.
Fiegl M; Lindner LH; Juergens M; Eibl H; Hiddemann W; Braess J
Cancer Chemother Pharmacol; 2008 Jul; 62(2):321-9. PubMed ID: 17922125
[TBL] [Abstract][Full Text] [Related]
8. Induction of ER and mitochondrial stress by the alkylphosphocholine erufosine in oral squamous cell carcinoma cells.
Ansari SS; Sharma AK; Soni H; Ali DM; Tews B; König R; Eibl H; Berger MR
Cell Death Dis; 2018 Feb; 9(3):296. PubMed ID: 29463797
[TBL] [Abstract][Full Text] [Related]
9. Reduced expression of the retinoblastoma protein shows that the related signaling pathway is essential for mediating the antineoplastic activity of erufosine.
Zaharieva MM; Kirilov M; Chai M; Berger SM; Konstantinov S; Berger MR
PLoS One; 2014; 9(7):e100950. PubMed ID: 24987858
[TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationship study of hypoxia-activated prodrugs for proteoglycan-targeted chemotherapy in chondrosarcoma.
Ghedira D; Voissière A; Peyrode C; Kraiem J; Gerard Y; Maubert E; Vivier M; Miot-Noirault E; Chezal JM; Farhat F; Weber V
Eur J Med Chem; 2018 Oct; 158():51-67. PubMed ID: 30199705
[TBL] [Abstract][Full Text] [Related]
11. Erufosine: a membrane targeting antineoplastic agent with signal transduction modulating effects.
Zaharieva MM; Konstantinov SM; Pilicheva B; Karaivanova M; Berger MR
Ann N Y Acad Sci; 2007 Jan; 1095():182-92. PubMed ID: 17404031
[TBL] [Abstract][Full Text] [Related]
12. The membrane-targeted alkylphosphocholine erufosine interferes with survival signals from the extracellular matrix.
Chometon G; Cappuccini F; Raducanu A; Aumailley M; Jendrossek V
Anticancer Agents Med Chem; 2014 May; 14(4):578-91. PubMed ID: 24628265
[TBL] [Abstract][Full Text] [Related]
13. Erufosine, an alkylphosphocholine, with differential toxicity to human cancer cells and bone marrow cells.
Bagley RG; Kurtzberg L; Rouleau C; Yao M; Teicher BA
Cancer Chemother Pharmacol; 2011 Dec; 68(6):1537-46. PubMed ID: 21526352
[TBL] [Abstract][Full Text] [Related]
14. Erufosine, a phosphoinositide-3-kinase inhibitor, to mitigate posterior capsule opacification in the human capsular bag model.
Wertheimer C; Brandlhuber U; Kook D; Mayer WJ; Laubichler P; Wolf A; Kampik A; Eibl-Lindner K
J Cataract Refract Surg; 2015 Jul; 41(7):1484-9. PubMed ID: 26210048
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and biodistribution of Erufosine in nude mice--implications for combination with radiotherapy.
Henke G; Lindner LH; Vogeser M; Eibl HJ; Wörner J; Müller AC; Bamberg M; Wachholz K; Belka C; Jendrossek V
Radiat Oncol; 2009 Oct; 4():46. PubMed ID: 19852786
[TBL] [Abstract][Full Text] [Related]
16. Structure-transfection activity relationships in a series of novel cationic lipids with heterocyclic head-groups.
Ivanova EA; Maslov MA; Kabilova TO; Puchkov PA; Alekseeva AS; Boldyrev IA; Vlassov VV; Serebrennikova GA; Morozova NG; Zenkova MA
Org Biomol Chem; 2013 Nov; 11(41):7164-78. PubMed ID: 24057052
[TBL] [Abstract][Full Text] [Related]
17. Hypoxia-selective antitumor agents. 16. Nitroarylmethyl quaternary salts as bioreductive prodrugs of the alkylating agent mechlorethamine.
Tercel M; Lee AE; Hogg A; Anderson RF; Lee HH; Siim BG; Denny WA; Wilson WR
J Med Chem; 2001 Oct; 44(21):3511-22. PubMed ID: 11585455
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Characterization of a Phosphate Prodrug of Isoliquiritigenin.
Boyapelly K; Bonin MA; Traboulsi H; Cloutier A; Phaneuf SC; Fortin D; Cantin AM; Richter MV; Marsault E
J Nat Prod; 2017 Apr; 80(4):879-886. PubMed ID: 28252963
[TBL] [Abstract][Full Text] [Related]
19. Erufosine simultaneously induces apoptosis and autophagy by modulating the Akt-mTOR signaling pathway in oral squamous cell carcinoma.
Kapoor V; Zaharieva MM; Das SN; Berger MR
Cancer Lett; 2012 Jun; 319(1):39-48. PubMed ID: 22202640
[TBL] [Abstract][Full Text] [Related]
20. Effects of ionizing radiation in combination with Erufosine on T98G glioblastoma xenograft tumours: a study in NMRI nu/nu mice.
Henke G; Meier V; Lindner LH; Eibl H; Bamberg M; Belka C; Budach W; Jendrossek V
Radiat Oncol; 2012 Oct; 7():172. PubMed ID: 23078969
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
